Gan & Lee Pharmaceuticals: U.S. Subsidiary GZR Phase I Clinical Trial Approved by U.S. FDA


2022-08-08: [Chinese Article Link] The Canary Pharmacy Industry announced on 8 August that recently, the wholly-owned subsidiary, Gan&LeePharmacuticalsUSACFORFORMENT, was notified by the United States FDA of its agreement to GZR4 to conduct the first phase of clinical trials. The GZR4 is an ultra-long insulin weekly formulation…


Note: This is a machine translated version of the Chinese news media article. A mature and nuanced reading is suggested.




Trending Topics


Trending News

What China Reads


Gan & Lee Pharmaceuticals: U.S. Subsidiary GZR Phase I Clinical Trial Approved by U.S. FDA


2022-08-08: [Article Link] The Canary Pharmacy Industry announced on 8 August that recently, the wholly-owned subsidiary, Gan&LeePharmacuticalsUSACFORFORMENT, was notified by the United States FDA of its agreement to GZR4 to conduct the first phase of clinical trials. The GZR4 is an ultra-long insulin weekly formulation…

Note: This is a translated version of the Chinese news media article. A mature and nuanced reading is suggested.